Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

6825 ARTÍCULOS , VIENDO DEL 5536 AL 5550

Molecular PET imaging in multicenter Alzheimer's therapeutic trials: current trends and implementation strategies

Seibyl J, Zubal IG, Jennings D, Marek K, Doraiswamy PM.

Expert Rev Neurother. 2011 Dec;11(12):1783-93. doi: 10.1586/ern.11.168.

PET amyloid-beta imaging in preclinical Alzheimer's disease

Vlassenko AG, Benzinger TL, Morris JC.

Biochim Biophys Acta. 2012 Mar;1822(3):370-9. doi: 10.1016/j.bbadis.2011.11.005. Epub 2011 Nov 12.

The future of Alzheimer's disease: the next 10 years

Hampel H, Prvulovic D, Teipel S, Jessen F, Luckhaus C, Frölich L, Riepe MW, Dodel R, Leyhe T, Bertram L, Hoffmann W, Faltraco F; German Task Force on Alzheimer's Disease (GTF-AD).

Prog Neurobiol. 2011 Dec;95(4):718-28. doi: 10.1016/j.pneurobio.2011.11.008. Epub 2011 Nov 22.

Blood-based biomarkers for Alzheimer's disease: plasma Aβ40 and Aβ42, and genetic variants

Mayeux R, Schupf N.

Neurobiol Aging. 2011 Dec;32 Suppl 1(Suppl 1):S10-9. doi: 10.1016/j.neurobiolaging.2011.09.004.

Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia

Klunk WE.

Neurobiol Aging. 2011 Dec;32 Suppl 1(Suppl 1):S20-36. doi: 10.1016/j.neurobiolaging.2011.09.006.

Potential of functional MRI as a biomarker in early Alzheimer's disease

Sperling R.

Neurobiol Aging. 2011 Dec;32 Suppl 1(Suppl 1):S37-43. doi: 10.1016/j.neurobiolaging.2011.09.009.

Alliance for aging research AD biomarkers work group: structural MRI

Jack CR Jr.

Neurobiol Aging. 2011 Dec;32 Suppl 1(0 1):S48-57. doi: 10.1016/j.neurobiolaging.2011.09.011.

Changes in cognition

Albert MS.

Neurobiol Aging. 2011 Dec;32 Suppl 1(0 1):S58-63. doi: 10.1016/j.neurobiolaging.2011.09.010.

The potential role of microRNA-146 in Alzheimer's disease: biomarker or therapeutic target?

Wang LL, Huang Y, Wang G, Chen SD.

Med Hypotheses. 2012 Mar;78(3):398-401. doi: 10.1016/j.mehy.2011.11.019. Epub 2011 Dec 29.

Molecular neuroimaging in Alzheimer's disease

Matsuda H, Imabayashi E.

Neuroimaging Clin N Am. 2012 Feb;22(1):57-65, viii. doi: 10.1016/j.nic.2011.11.005. Epub 2011 Dec 6.

Alzheimer's disease (AD) and executive dysfunction. A case-control study on the significance of frontal white matter changes detected by diffusion tensor imaging (DTI)

Sjöbeck M, Elfgren C, Larsson EM, Brockstedt S, Lätt J, Englund E, Passant U.

Arch Gerontol Geriatr. 2010 May-Jun;50(3):260-6. doi: 10.1016/j.archger.2009.03.014. Epub 2009 May 5.

[Workplace health promotion through human resources development part I: development and evaluation of qualification programme for prevention of psychic stresses]

Zimber A, Gregersen S, Kuhnert S, Nienhaus A.

Gesundheitswesen. 2010 Apr;72(4):209-15. doi: 10.1055/s-0029-1214403. Epub 2009 Jun 16.

The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease

Rockwood K, Fay S, Gorman M.

Int J Geriatr Psychiatry. 2010 Feb;25(2):191-201. doi: 10.1002/gps.2319.

Preliminary evidence of validity of the revised criteria for Alzheimer disease diagnosis: report of 2 cases

Frisoni GB, Galluzzi S, Signorini M, Garibotto V, Paghera B, Binetti G, Canu E, Geroldi C, Perani D.

Alzheimer Dis Assoc Disord. 2010 Jan-Mar;24(1):108-14. doi: 10.1097/WAD.0b013e3181a1fd34.

Working memory in early Alzheimer's disease: a neuropsychological review

Huntley JD, Howard RJ.

Int J Geriatr Psychiatry. 2010 Feb;25(2):121-32. doi: 10.1002/gps.2314.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias